John M. Evans, CEO at Beam Therapeutics Inc. (BEAM), sold 37,283 shares at $108.65 ($4.0M) on 2021-07-07, disclosed to the SEC on 2021-07-08.
Open-market sale of $4.0M BEAM by CEO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $100.69 | 645 | $65K | 1.6% |
| 2 | $100.69 | 645 | $65K | 1.6% |
| 3 | $101.27 | 2,300 | $233K | 5.8% |
| 4 | $102.00 | 100 | $10K | 0.3% |
| 5 | $103.52 | 2,864 | $296K | 7.4% |
| 6 | $103.52 | 2,864 |
| $296K |
| 7.4% |
| 7 | $104.40 | 1,336 | $139K | 3.5% |
| 8 | $104.40 | 1,336 | $139K | 3.5% |
| 9 | $105.44 | 1,800 | $190K | 4.7% |
| 10 | $106.48 | 500 | $53K | 1.3% |
| 11 | $107.31 | 167 | $18K | 0.4% |
| 12 | $108.65 | 800 | $87K | 2.2% |
| 13 | $109.58 | 4,800 | $526K | 13.1% |
| 14 | $110.54 | 3,982 | $440K | 10.9% |
| 15 | $110.54 | 3,982 | $440K | 10.9% |
| 16 | $111.51 | 3,456 | $385K | 9.6% |
| 17 | $111.51 | 3,456 | $385K | 9.6% |
| 18 | $112.62 | 2,250 | $253K | 6.3% |
| Total | $107.91 avg | 37,283 | $4.0M | 100% |
| Filing → |
| BEAM | SELL | 2026-04-01 | $1.1M | — | Filing → |
| BEAM | SELL | 2026-02-02 | $2.8M | — | Filing → |
| BEAM | SELL | 2025-10-03 | $1.2M | — | Filing → |